Inventiva (NASDAQ:IVA) Releases Earnings Results, Misses Expectations By $0.57 EPS

Inventiva (NASDAQ:IVA) released its quarterly earnings data on Monday. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.57), reports. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $8.67 million.

Inventiva Trading Up 1.2%

NASDAQ:IVA opened at $5.55 on Wednesday. The stock has a 50-day simple moving average of $6.26 and a 200 day simple moving average of $5.37. Inventiva has a 52-week low of $2.85 and a 52-week high of $7.98.

Hedge Funds Weigh In On Inventiva

Large investors have recently bought and sold shares of the company. Yu Fan acquired a new stake in shares of Inventiva in the fourth quarter valued at approximately $6,975,000. RTW Investments LP acquired a new position in Inventiva during the fourth quarter worth $6,039,000. J. Goldman & Co LP bought a new position in Inventiva in the fourth quarter valued at $2,401,000. Ikarian Capital LLC bought a new position in Inventiva in the fourth quarter valued at $2,329,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Inventiva in the 4th quarter valued at $2,325,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Analysts Set New Price Targets

IVA has been the topic of several research analyst reports. Truist Financial began coverage on shares of Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 target price on the stock. HC Wainwright set a $24.00 price target on shares of Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th. Barclays initiated coverage on shares of Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. Finally, UBS Group began coverage on shares of Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Inventiva presently has an average rating of “Buy” and an average price target of $16.56.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.